Related references
Note: Only part of the references are listed.Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation An Instrumental Variable Analysis of a Nationwide Cohort
Anders N. Bonde et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2020)
Finding Order in Chaos Can Instrumental Variables Help Us Understand Observed Treatment Effects?
Yao Xiaoxi et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2020)
Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records
Krista F. Huybrechts et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
Brandon K. Martinez et al.
PHARMACOTHERAPY (2019)
Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation
Fahad Shaikh et al.
CURRENT CARDIOLOGY REPORTS (2018)
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients The ARISTOPHANES Study
Gregory Y. H. Lip et al.
STROKE (2018)
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in real-world clinical practice
Xiaoyan Li et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Stroke prevention in atrial fibrillation: Past, present and future Comparing the guidelines and practical decision-making
Gregory Y. H. Lip et al.
THROMBOSIS AND HAEMOSTASIS (2017)
What is polypharmacy? A systematic review of definitions
Nashwa Masnoon et al.
BMC GERIATRICS (2017)
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation
Jonathan P. Piccini et al.
CIRCULATION (2016)
Warfarin-drug interactions: An emphasis on influence of polypharmacy and high doses of amoxicillin/clavulanate
Mahmoud I. Abdel-Aziz et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
Jeroen Jaspers Focks et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
Jeroen Jaspers Focks et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010
Bruce Guthrie et al.
BMC MEDICINE (2015)
Validity of International Classification of Disease Codes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation
Jonathan L. Thigpen et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)
Validity of International Classification of Disease Codes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation
Jonathan L. Thigpen et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)
The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments
Peter C. Austin
STATISTICS IN MEDICINE (2014)
An automated database case definition for serious bleeding related to oral anticoagulant use
Andrew Cunningham et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Peter C. Austin
STATISTICS IN MEDICINE (2009)
Adverse drug reactions as cause of hospital admissions: Results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA)
G Onder et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2002)
Share Paper
